newsfilter
← Latest News
GlobeNewswire·

Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026

  • Immix Biopharma will present NXC-201 safety & efficacy data at the 68th ASH Annual Meeting in New Orleans from December 12-15, 2026.
  • The abstract titled "45-patient safety and efficacy data for NXC-201 from Nexicart-2" will be presented on Monday, December 14, 2026, at 11:15 AM CDT.
  • The presentation occurs in session 652 regarding clinical strategies for AL Amyloidosis.
  • AL Amyloidosis is the most common form of amyloidosis, affecting approximately 30,506 patients in the U.S. with relapsed/refractory disease in 2026.
  • The U.S. AL Amyloidosis market was valued at $6.2 billion in 2025 and is projected to reach $6.6 billion in 2026.
  • NXC-201 is a sterically-optimized BCMA-targeted CAR-T therapy being evaluated in the U.S. NEXICART-2 trial for relapsed/refractory AL Amyloidosis.
  • NXC-201 has received Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy status, Orphan Drug Designation by the FDA, and Orphan Drug Designation by the EMA.